Notably, 3 out of 5 responses were seen in patients with NRAS mutations, which highlights that not only in MDS and AML but also in CMML patients, an individualized approach to treatment selection might be possible [133]. The gene discussed is NRAS; the disease is acute myeloid leukemia.